Rowen Chlebowski
Hematology & Oncology · Torrance, CANPI 1902876386
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $52,559 of the $67,773 with a category attached, or 77.6%. 22 manufacturers reported payments, led by AstraZeneca at 48.0% of the total. Reporting peaked in 2019 at $54,695 and has fallen 100.0% since, to $12 in 2021. Among hematology & oncology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 122 payments — averaging $555.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$33K
- Novartis$17K
- Eisai CO., LTD.$9K
- Puma Biotechnology, Inc.$4K
- Amgen$3K
- Athenex Pharmaceutical Division, LLC$1K
- plus $1K from 16 others
What the payments were for
- Consulting fees$6,50010%
- Speaking & faculty fees$52,55978%
- Travel & lodging$6,3859%
- Food & beverage$2,2923%
- Education$380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 28 | $32,542 |
| Novartis | 19 | $16,786 |
| Eisai CO., LTD. | 1 | $9,469 |
| Puma Biotechnology, Inc. | 5 | $3,577 |
| Amgen | 2 | $3,332 |
| Athenex Pharmaceutical Division, LLC | 3 | $1,022 |
| Genentech USA, Inc. | 13 | $263 |
| E.r. Squibb & Sons, L.L.C. | 16 | $230 |
| Pfizer | 14 | $128 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $71 |
| Sanofi | 3 | $67 |
| Regeneron Healthcare Solutions, Inc. | 2 | $48 |
| Eisai Inc. | 2 | $45 |
| Sanofi-aventis U.S. LLC | 2 | $45 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $39 |
| Seagen Inc. | 1 | $23 |
| Incyte Corporation | 1 | $19 |
| Stemline Therapeutics Inc. | 1 | $17 |
| Merck | 1 | $15 |
| Emmaus Medical, Inc. | 1 | $14 |
| Gilead | 1 | $12 |
| Bayer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYNPARZA$32,182
- KISQALI$16,466
- PIQRAY$12,281
- Halaven$9,469
- Nerlynx$3,400
- XGEVA$3,300
- Oral Paclitaxel$1,000
- Encequidar$1,000
How this compares
$67,773 in reported general payments places this provider in the 90th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Torrance
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
- Catherine CoombsOrange$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.